Other News To Note
Wednesday, May 23, 2012
Cytos Biotechnology Ltd., of Zurich, Switzerland, said it completed a CHF23.75 million (US$25.2 million) equity investment. The financing is part of a planned CHF37 million debt and equity deal to be provided by an international syndicate of investors, including venBio, Abingworth, Aisling Capital and Amgen. Cytos intends to use the proceeds primarily to conduct a Phase IIb study of CYT003 in allergic asthma.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.